Lokelma, a treatment for hyperkalemia, has several patents protecting its intellectual property. These patents are crucial for the drug's market exclusivity.
When does Lokelma's patent protection expire?
The specific expiration dates for Lokelma's patents vary. For instance, U.S. Patent No. 8,993,571, which relates to the composition of matter for Lokelma (sodium zirconium cyclosilicate), is listed as expiring on September 30, 2028 [1]. Other patents covering different aspects of the drug may have different expiration timelines. Information on patent status and expiration can often be found on resources like DrugPatentWatch.com [2].
What is Lokelma used for?
Lokelma is a potassium binder approved for the treatment of hyperkalemia, a condition characterized by dangerously high levels of potassium in the blood. It works by binding to potassium in the gastrointestinal tract, thereby reducing serum potassium levels [3].
Who makes Lokelma?
Lokelma is developed and marketed by AstraZeneca [3].
Are there challenges to Lokelma's patents?
Patent challenges are common in the pharmaceutical industry, especially as a drug approaches the end of its exclusivity period. Companies often seek to invalidate existing patents or demonstrate that their own products do not infringe upon them. While specific litigation details for Lokelma's patents are not provided here, such challenges are a typical part of the drug patent landscape. DrugPatentWatch.com tracks patent litigation and status for many drugs [2].
What is the mechanism of action for Lokelma?
Lokelma is a selective potassium binder. Its active ingredient, sodium zirconium cyclosilicate, is an insoluble powder that, when ingested, exchanges sodium ions for potassium ions within the gastrointestinal tract. This binding action removes excess potassium from the body, helping to lower serum potassium concentrations [3].
How does Lokelma compare to other hyperkalemia treatments?
Lokelma offers a rapid onset of action in reducing potassium levels, which is a key differentiator for treatments of hyperkalemia. Other potassium binders include patiromer (Veltassa) and older, less selective agents like sodium polystyrene sulfonate (Kayexalate, Kionex). Lokelma's selectivity for potassium over other cations like magnesium and calcium is a noted characteristic [3].
What are the clinical trial results for Lokelma?
Clinical trials have demonstrated Lokelma's efficacy in reducing and maintaining serum potassium levels in patients with hyperkalemia. Studies have shown a rapid reduction in potassium levels within the first hour and sustained control over longer periods [3].
What are the risks associated with Lokelma?
Common side effects of Lokelma include gastrointestinal issues such as constipation and diarrhea. It is also important for patients to monitor for edema, particularly in individuals with heart failure. The drug's binding properties mean it can affect the absorption of other orally administered medications [3].
Can generic versions of Lokelma be developed?
The development of generic versions of Lokelma is contingent upon the expiration of its relevant patents and regulatory approval. Once patents expire and any remaining market exclusivity periods conclude, generic manufacturers can seek approval to market their own versions of the drug, typically at a lower cost. DrugPatentWatch.com provides detailed information on patent expiry and exclusivity for pharmaceuticals [2].
Sources:
[1] https://www.drugpatentwatch.com/p/lokelma-patent-us8993571
[2] https://www.drugpatentwatch.com/
[3] https://www.astrazeneca.com/our-products/lokelma.html